Evotec vs Protagonist Therapeutics
EVO and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVO and PTGX compare
Protagonist Therapeutics grew revenue faster over the last twelve months (164% versus −1.1% for Evotec).
Protagonist Therapeutics scores higher on the StockData Score (16 against 4 for Evotec), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVO | PTGX |
|---|---|---|
| Size and price | ||
| Market cap | – | $8.7B |
| Share price | $1.69 | $134.86 |
| Change, 1 year | −43.5% | 62.0% |
| Change, 5 years | −92.9% | 285% |
| Beta (5Y) | 1.26 | 0.79 |
| Employees | 4,553 | 132 |
| StockData Score | ||
| Total score | 4 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 28.6× |
| P/S | – | 15.8× |
| P/B | – | 8.0× |
| EV/EBITDA | – | 24.4× |
| P/FCF | – | 80.0× |
| FCF yield | – | 1.3% |
| Fair value | – | $183.58 |
| Margin of safety | – | 26.5% |
| Growth | ||
| Revenue growth (TTM) | −1.1% | 164% (better) |
| Revenue growth, 5Y average | 9.5% | 10.0% (better) |
| Net income growth (TTM) | – | 646% |
| EPS growth (TTM) | – | 661% |
| Profitability | ||
| Gross margin | 14.5% | – |
| Operating margin | −7.1% | 58.6% (better) |
| Net margin | – | 62.0% |
| FCF margin | −10.4% | 19.8% (better) |
| Return on equity | – | 39.6% |
| Return on invested capital | −7.7% | 178% (better) |
| Financial health | ||
| Debt / equity | 0.10 (better) | 0.00 |
| Net debt / EBITDA | −7.79 | – |
| Current ratio | 2.07 | 19.85 (better) |
| Altman Z-score | – | 87.35 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.8% | 117% |
| Held by insiders | 17.1% | 1.7% |
| Insider net buying, 12 months | – | −$95.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 16.1% |
Go deeper
- EVO stock overview
- EVO income statement
- EVO valuation and score
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.